What was Merck's revenue in Q1 2026?

Merck's revenue was $16.29 billion, up 4.9% year over year.

Did Merck beat expectations in Q1?

Yes, revenue beat estimates, and non-GAAP loss per share beat analysts' consensus by 13.2%.

What is Merck's full-year 2026 revenue guidance?

Merck expects full-year revenue of approximately $66.4 billion.

Which segment drove Merck's growth in Q1?

The oncology segment led growth, along with new product launches.

What was Merck's non-GAAP loss per share in Q1?

Non-GAAP loss per share was $1.28.

Merck Beats Q1 2026 Estimates with $16.29B Revenue, Oncology Strength

Merck (NYSE:MRK) announced better-than-expected Q1 2026 revenue, driven by strong oncology performance and new product launches. Revenue reached $16.29 billion, up 4.9% year over year, while non-GAAP loss of $1.28 per share beat analysts' estimates by 13.2%.

Global pharmaceutical company Merck (NYSE:MRK) reported better-than-expected revenue for the first quarter of 2026, driven by strength in its oncology segment and contributions from recently launched products. Revenue came in at $16.29 billion, up 4.9% year over year, while non-GAAP loss per share of $1.28 beat analysts' consensus estimates by 13.2%.

Key Financial Results

Metric	Q1 2026	vs. Estimates
Revenue	$16.29B	Beat
YoY Growth	+4.9%	-
Non-GAAP EPS	-$1.28	Beat by 13.2%

Highlights from the Release

Merck attributed the strong performance to growth in oncology drug sales and the ramp-up of new product launches. The company also noted achieving key pipeline milestones during the quarter.

Guidance

For the full year 2026, Merck expects revenue of approximately $66.4 billion, close to analysts' estimates.

Impact on the Stock

The stock reaction was not specifically mentioned in the report, but beating expectations typically provides short-term support.

What This Means for Investors

Merck's results demonstrate the strength of its core business, particularly in oncology, with continued growth driven by innovation. The stable full-year guidance provides confidence in the company's performance for the current year.